New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma

Click here to view online. Add this email to your safelist.

17 May 2018

AstraZeneca today announced results from the Phase III SYGMA trialsof Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma. The data are published in the New England Journal of Medicine and will be presented on Sunday 20 May at the American Thoracic Society (ATS) 2018 International Congress.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.